Long-term Survival Outcomes for Men Who Provided Ejaculate Specimens for Prostate Cancer Research: Implications for Patient Management  by Ashrafi, Darius et al.
Prostate Cancer
Long-term Survival Outcomes for Men Who Provided Ejaculate
Specimens for Prostate Cancer Research: Implications for Patient
Management
Darius Ashrafi a,b, Peter Baade c,d,e, John Yaxley f, Matthew J. Roberts a,b, Scott Williams g,
Robert A. Gardiner a,b,f,h,*
a School of Medicine, University of Queensland, Brisbane, Australia; bCentre for Clinical Research, University of Queensland, Brisbane, Australia; cCancer
Council Queensland, Brisbane, Australia; d School of Public Health & Social Work, Queensland University of Technology, Brisbane, Australia; eGriffith Health
Institute, Griffith University, Brisbane, Australia; fRoyal Brisbane & Women’s Hospital, Brisbane, Australia; g Peter Macallum Cancer Centre, University of
Melbourne, Melbourne, Australia; h Edith Cowan University, Perth, Australia
E U R O P E A N U R O L O G Y F O C U S 1 ( 2 0 1 5 ) 2 0 0 – 2 0 6
avai la ble at www.sciencedirect .com
journal homepage: www.europeanurology.com/euf ocus
Article info
Article history:
Accepted April 3, 2015
Associate Editor:
Gianluca Giannarini
Keywords:
Survival outcomes
Ejaculate specimens
Prostate cancer detection
Abstract
Background: Determining whether men diagnosed with early prostate cancer (PCa) will
live long enough to benefit from interventions with curative intent is difficult. Although
validated instruments for predicting patient survival are available, these do not have
clinical utility so are not used routinely in practice.
Objective: To test the hypothesis that volunteers who provided ejaculate specimens had
a high survival rate at 10 and 15 yr and beyond.
Design, setting, and participants: A total of 290 patients investigated because of high
serum prostate-speciﬁc antigen donated ejaculate specimens for research between
January 1992 and May 2003. The median age at the time of ejaculation was 63.5 yr.
153 of the donors were diagnosed with PCa and followed up to December 31, 2013.
Outcome measurements and statistical analysis: Survival outcomes were compared
with those for the whole population, as indicated by life expectancy tables up to 20 yr.
Results and limitations: Men in the PCa group had life expectancies comparable with
values listed in life expectancy tables for the whole population. Overall, PCa-speciﬁc and
relative survival were signiﬁcantly better for men in the non-PCa and PCa groups in
comparison with men diagnosed with PCa in Queensland during the same period.
Relative survival for those aged 20–49, 50–64, and 65 yr was >100% for ejaculate
donors and 81.5%, 82.7%, and 65.2%, respectively, for the Queensland Cancer Registry
reference at 10 yr. These ﬁndings for this highly selected patient cohort support the
hypothesis that an ability to provide an ejaculate specimen is associated with a high
likelihood of surviving 10–20 yr after donation, whether or not PCa was detected.
Conclusion: Life expectancy tables may serve as a quick and simple life expectancy
indicator for biopsy patients who donate ejaculate.
Patient summary: Life expectancy tables indicated survival of up to 20 yr for men who
provided ejaculate specimens for prostate cancer research.
# 2015 European Association of Urology. Published by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/* Corresponding author. Un
Brisbane and Women’s Hos
Tel. +61 7 3346 6071; Fax:
E-mail address: f.gardiner@
http://dx.doi.org/10.1016/j.euf.2015.04.002
2405-4569/# 2015 European Association of Urology. Published by Elsevier B
creativecommons.org/licenses/by-nc-nd/4.0/).by-nc-nd/4.0/).iversity of Queensland Centre for Clinical Research, Building 71 Royal
pital, 918 Bowen Bridge Road, Herston, Queensland 4029, Australia.
 +61 7 3346 5599.
uq.edu.au (R.A. Gardiner).
.V. This is an open access article under the CC BY-NC-ND license (http://
E U R O P E A N U R O L O G Y F O C U S 1 ( 2 0 1 5 ) 2 0 0 – 2 0 6 2011. Introduction
Selecting the most appropriate management for men with
early prostate cancer (PCa) is beset by many uncertainties
[1,2]. Prominent among these is predicting which patients
will live long enough to benefit from interventions with
curative intent given the long natural history of PCa and the
age groups involved. In terms of survival, life expectancy of
at least 10 yr is generally accepted as required to justify
treatment and therefore testing [3,4].
Published evidence indicates that doctors are less than
perfect in estimating survival [5]. In the Prostate Cancer
Intervention versus Observation Trial (PIVOT) of radical
prostatectomy (RP) and observation for localized PCa, 47.0%
randomised to RP died during a median follow-up of 10.0 yr,
compared with 49.9% assigned to observation; 5.8% died from
PCa or treatment in the RP group compared with 8.4% in the
observation arm [6]. In the randomised Swedish trial of RP
versus watchful waiting (WW), 57.6% in the RP group and 70%
in the WW group had died, 12.4% and 28.4%, respectively,
from PCa, during a median follow-up of 13.4 yr [7]. Compara-
ble outcomes have been observed following radiation therapy
[8]. Daskivich et al [9] observed from the Surveillance,
Epidemiology, and End Results-Medicare database that for
96 032 men aged >66 yr with early-stage PCa (Gleason 7)
diagnosed during 1991–2007, 52% had life expectancy <10
yr, and nearly half had received aggressive treatment.
Although validated instruments are available for investi-
gating general comorbidity-related deaths [10], none has
become established in routine clinical use on a day-to-day
basis, reflecting findings from a systematic review that found
none of the life expectancy prediction tools available for
localised PCa patients is sufficiently adequate to justify
implementation into clinical practice [11]. It has recently
become apparent that the onset of erectile dysfunction (ED)
serves to herald fatal events from cardiovascular disease
[12]. One large study reported a median time to death from a
cardiovascular cause following the onset of ED to be 10 yr [13]
since the reason for ED in the majority of cases is impaired
arterial flow [12]. However, assessment of ED through patient
histories and validated instruments is problematic because of
the unreliability of patient reporting in questionnaires such as
the International Index of Erectile Function (IIEF) [14,15].
We have been studying ejaculate as part of our early PCa
research studies for many years, and hypothesised that
these volunteers, all of whom had been vetted by urologists
and were considered for treatment with curative intent
should significant PCa be detected, would have a high
survival rate, and that the ability to provide an ejaculate
specimen would hence serve as a simple indicator of life
expectancy. Thus, the aim of this study was to examine the
survival outcomes for men who provided ejaculate speci-
mens before 2003 for our research studies.
2. Patients and methods
2.1. Patients
Between January 1992 and May 2003, men referred to the Urology Unit
of the Royal Brisbane and Women’s Hospital (RBWH) (93%) or attendinga urologist privately (7%) for investigation of abnormal prostate-speciﬁc
antigen (PSA) with or without an abnormal digital rectal examination
(DRE) were approached to volunteer a specimen of ejaculate for our
research into early diagnosis of PCa. All were booked to have a diagnostic
transrectal ultrasound (TRUS)-guided biopsy. Ejaculate specimens were
provided before or 1 mo after biopsy.
2.2. Histology and PSA
Histologic diagnoses were obtained from the Queensland Cancer
Registry and cross-checked with Queensland Health databases, institu-
tional research ﬁles, and the ﬁles of relevant private pathology
laboratories. Serum PSA levels before ejaculate donation and biopsy
procedures were also obtained by interrogating the databases of
Queensland Health and private Queensland pathology laboratories.
2.3. Patient outcomes
Dates and causes of death were obtained from the Queensland Health
Hospital Business Corporate Information Services programme, Queens-
land Cancer Registry, patient hospital notes, relevant research databases,
and private doctors’ records, and were conﬁrmed via the National Death
Index.
2.4. Ethical approval
Human research ethics approval was given by the University of
Queensland (project no. 2006000262) and from RBWH ethics commit-
tees (94/29; 1995/088B) with access to the Queensland Cancer Registry
data approved by Queensland Health.
2.5. Measures
The cohort was stratiﬁed into three groups (biopsy positive, biopsy
negative, and no biopsy performed) according to their biopsy status for
PCa. PSA before ejaculate donation (<4 ng/ml, 4–10 ng/ml, and >10 ng/
ml) and patient age at the time of ejaculation (modelled as a continuous
variable but reported in categories of <50 yr, 50–65 yr, and >65 yr) were
considered in the analyses and compared with Queensland population
10–yr survival data for PCa diagnoses during 1993–2003.
2.6. Statistical analysis
Survival times were taken from the date of ejaculate donation to the date
of death or December 31, 2013, whichever came ﬁrst. Men not known to
have died by December 31, 2013 were considered alive, and therefore
censored in the survival analysis. Median potential follow-up time was
calculated using the reverse Kaplan-Meier method [16].
Our primary outcome of interest was all-cause survival. Kaplan-
Meier survival curves were generated for the total cohort and stratiﬁed
by biopsy status, PSA before ejaculate donation, and age group at the
time of ejaculation.
In the absence of comparative data for men who did not provide
ejaculate specimens during the study period, we used total population
and cancer registry data as the comparison groups. Differences observed
using this methodology are thus likely to be biased toward the null
compared with the true value. We used relative survival to compare all-
cause survival outcomes among the cohort with that for the age- and
sex-matched population. The Ederer II method [17] was used to calculate
expected survival.
While previous studies have used generalised linear models with a
Poisson error structure to model excess mortality, convergence issues
when the cohort mortality is less than for the general population [18]
necessitated comparison of relative survival estimates for subgroups
Table 2 – Cancer causes of death other than prostate cancer
Cancer causing death No prostate cancer Prostate
Biopsy
(n = 100)
No biopsy
(n = 37)
cancer
(n = 153)
Lung 5 1 2
Colorectal 1 3
Brain 1 1
Pancreas 1 2
Lymphoma 1 1 2
Bladder 1
Renal 1
Oesophageal 1
Melanoma 1
Cholangiocarcinoma 1
Gastric 1
Total 10 5 12
Table 1 – Cohort characteristics by cancer group and 10-yr all-cause survival
Total cohort No prostate cancer found Prostate cancer
n 10-yr survival, % (95% CI) n 10-yr survival, % (95% CI) n 10-yr survival, % (95% CI)
Cohort 290 83.5 (79–87) 137 89.1 (83–93) 153 78.4 (71–84)
Age at ejaculate donation
20–49 yr 25 100.0 19 100.0 6 100.0
50–65 yr 151 91.4 (86–95) 74 94.6 (86–98) 77 88.3 (78-94)
>65 yr 113 69.0 (60–77) 44 75.0 (59–85) 69 65.2 (53–75)
Unknown 1 0 1
PSA value
<4.0 ng/ml 80 88.8 (80–94) 51 90.2 (78–96) 29 86.2 (67–96)
4.0–10 ng/ml 95 87.4 (79–93) 44 88.6 (75–95) 51 86.3 (73–93)
>10 ng/ml 87 70.1 (59–79) 27 85.2 (65–94) 60 63.3 (50–74)
No PSA 28 96.4 (77–99) 15 93.3 (61–99) 13 100.0
Follow-up
<5 yr 20 Not applicable 6 Not applicable 14 Not applicable
5–9 yr 28 9 19
10–14 yr 80 24 56
15 yr 162 98 64
CI = conﬁdence interval.
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When the 95% CI for a relative survival estimate did not include one,
survival in this group was considered signiﬁcantly different to that of the
general population.
For all-cause survival, ﬂexible parametric survival models [19,20]
were used to examine the impact of covariates. Flexible parametric
survival models were ﬁtted on the log cumulative hazard scale [19,20]
with natural cubic splines to estimate the baseline log cumulative excess
hazard function. We used the hazard scale with four degrees of freedom,
with a forward selection process to determine the time dependence of
any regression coefﬁcients [19]. We plotted average predicted subgroup-
speciﬁc survival estimates from the ﬂexible parametric model with the
observed Kaplan-Meier survival estimates for that subgroup, and
tabulated predicted 20-yr survival probabilities with 95% CIs for speciﬁc
combinations of the covariates. Age was modelled as a continuous
variable with incorporation of a smooth rank transform [20].
3. Results
A total of 290 eligible men provided specimens at a median
age of 63.5 yr (Table 1). The median follow-up was 16.9,
16.1, and 17.3 yr for the total, PCa, and no-PCa cohorts
respectively. The median follow-up was 10.7 yr (1.0–19.0
yr) for the 103 men who died from any cause from the date
of ejaculate donation and 16.6 yr (10.9–20.5 yr) for those
still alive at the time of data review. A biopsy-confirmed
diagnosis of PCa was made for 153 patients; 137 did not
have PCa detected, but 37 of these men elected not to
proceed to biopsy. The majority of men were aged 50–65 yr
at the time of ejaculate donation (Table 1), with 113 (39.1%)
>65 yr. PSA measurement was obtained for 90% of the
cohort, with values similarly split between the <4 ng/ml, 4–
10 ng/ml, and >10 ng/ml categories.
Of the 103 men known to have died during the study
period, 15 were certified as having died of cardiovascular
disease, 27 from other cancers (Table 2), 29 from PCa, and
20 of other causes; for the remaining 12 who died, no
information about the cause of death was available.3.1. All-cause survival
All-cause Kaplan-Meier survival estimates (Table 3, Fig. 1)
demonstrate better survival outcomes experienced by men
with no PCa (79% survival after 15 yr) than men diagnosed
with PCa (57.8% survival after 15 yr).
Visual comparisons between the subgroup-specific
Kaplan-Meier all-cause survival estimates and modelled
survival curves (Fig. 2) show strong agreement, suggesting
an appropriate fit of the survival model.
From the multivariate survival model, adjusted survival
probability (all causes) decreased as age increased (Table 5,
Fig. 2) and PSA levels increased, and was higher for men
without a cancer diagnosis.
3.2. Comparisons with the general population (relative
survival)
Examination of relative survival estimates (Table 4 and
Fig. 3) showed that the relative survival for men who had no
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Fig. 2 – Modelled (flexible parametric model, thick lines) and observed (Kaplan
group, (B) age at ejaculate donation, and (C) prostate-specific antigen level.
Table 3 – All-cause survival observed and median age at ejaculate donation
Follow-up All participants (n = 290) No prostate cancer (n = 137) Prostate cancer (n = 153)
Median age,
yr (n)
Survival,
%, (95% CI)
Median age,
yr (n)
Survival,
%, (95% CI)
Median age,
yr (n)
Survival,
%, (95% CI)
5 yr 63 (269) 93.1 (90–95) 61 (131) 95.6 (91–98) 65 (138) 90.1 (85–94)
10 yr 62 (241) 83.5 (79–87) 61 (122) 89.1 (83–93) 64 (119) 78.4 (71–84)
15 yr 61 (161) 68.1 (62–73) 59 (98) 79.2 (71–85) 63 (63) 57.8 (49–65)
20 yr 63 (3) 50.0 (37–62) 65 (2) 62.7 (42–78) 63 (1) 36.9 (19–55)
CI = conﬁdence interval.
Note that the group with no prostate cancer includes 37 participants who did not proceed to biopsy.
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Fig. 1 – Kaplan-Meier all-cause survival estimates by diagnostic group.
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donation. These men had a substantially better survival
outcome (or negative excess mortality) than the age-
matched male general population at 10 yr or more after
ejaculate donation, with many of the lower limits of the 95%
CIs in Figure 3 not including 100%. By contrast, relative
survival for men diagnosed with PCa tended to decrease
across the follow-up interval, while they continued to have
equivalent mortality expectations to those of the general
population, since the CIs included 100%.
Tables 6 and 7 detail 10-yr survival findings for the study
cohort and the Queensland male population. Overall, PCa-
specific and relative survival were significantly better for
the study cohort than for the whole of Queensland, with
findings most pronounced for those aged 65 yr.
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Table 5 – Adjusted 10-yr all-cause survival estimates from the full
model for the total cohort (n = 290)
Survival (%) 95% CI (%)
Age at ejaculate donation a
20–49 yr 97.5 96–99
50–65 yr 90.7 88–94
>65 yr 69.8 64–77
PSA value
<4.0 ng/ml 89.2 85–94
4.0–10 ng/ml 89.3 85–94
>10 ng/ml 67.3 60–75
No PSA 94.1 89–100
Diagnostic group
No prostate cancer 90.6 87–94
Prostate cancer 76.3 71–82
CI = conﬁdence interval.
a Age at ejaculate donation was modelled as a transformed continuous
variable, and then predicted survival probabilities were collapsed over these
groups.
Table 4 – Relative survival observed
Follow up Relative survival, % (95% conﬁdence interval)
All
participants
(n = 290)
No
prostate cancer
(n = 137)
Prostate
cancer
(n = 153)
0–5 yr 102.0 (98–105) 103.0 (97–106) 101.1 (95–105)
5–10 yr 103.1 (97–108) 105.7 (98–111) 100.6 (91–108)
10–15 yr 98.0 (90–114) 106.7 (96–115) 88.3 (75–100)
15–20 yr 104.6 (90–114) 115.2 (99–128) 88.0 (68–107)
Note that the group with no prostate cancer includes 37 participants who
did not proceed to biopsy.
Table 6 – Survival at 10 yr for men included in the ejaculate cohort
and diagnosed with prostate cancer (PCa) according to age at
ejaculate donation
Age group Survival (%)
Overall PCa-speciﬁc Relative
20–49 yr 100 100 103.0
50–64 yr 88.3 92.0 100.2
65 yr 65.2 86.2 100.2
All ages combined 78.4 90.1 100.6
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Survival results for participants, all of whom provided an
ejaculate specimen at least 10 yr (and up to 21 yr) before theTable 7 – Survival at 10 yr for men diagnosed with prostate cancer (PCa
cancer registry
Age at diagnosis Diagnoses
(n)
Deaths within 10 yr of diagnosis (n) a
PCa Other cancers Non-cancer 
20–49 yr 213 40 <10 <10 
50–64 yr 4999 821 240–250 280–290 
65 yr 16 511 4,247 1424 4749 
Total 21 723 5,108 1670 5036 
a Some data are presented as a range rather than a specific value because of lowcut-off time for analysis (December 31, 2013), strongly
support the hypothesis that volunteers who provided
ejaculate specimens for our research studies had a high
survival rate at 10, 15, and 20 yr. Overall, PCa-specific and
relative survival findings were significantly better for all age
groups in favour of the study cohort, and were most
pronounced in those aged 65 yr. In addition, we found a
close survival correlation with men of the same age as
indicated by life expectancy tables for Queensland males for
those diagnosed with PCa, raising the prospect that this
ready reference could serve as a simple indicator of life
expectancy. For those in whom PCa was not detected,
survival prospects to 20 yr increasingly exceeded those of
their age-matched contemporaries in the general popula-
tion.
Having detailed information for an overall median
follow-up of 15.6 yr, with 10.4 yr for those who died and
16.6 yr for those still alive at 10.9–20.5 yr after they
provided their ejaculate specimen, allowed us to determine
more than just projected outcomes via Kaplan-Meier
estimates. In addition to actual overall data, we could
estimate relative survival. We believe that relative survival
is much more clinically relevant as it permits direct
comparison of an individual’s survival data with peer data
as recorded in population life expectancy tables, since
placing survival prospects in the context of age norms is
most relevant in judging clinical applicability, particularly
for patients aged 65 yr. However, predicting outcome at an) in Queensland between 1993 and 2003 according to the Queensland
Alive 10 yr
after diagnosis (n)
Survival, % (95% conﬁdence interval)
Overall PCa-speciﬁc Relative
163 77.2 (71–82) 81.5 (76–86) 79.3 (73–85)
3655 73.1 (72–74) 82.7 (82–84) 81.7 (80–83)
6091 37.5 (37–38) 68.4 (68–69) 65.2 (64–67)
9909 46.1 (45–47) 72.4 (72–73) 70.1 (69–71)
 numbers.
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particularly for those who developed other cancers [21],
none of whom survived to 20 yr following specimen
donation, reflecting the shorter natural histories of these
other malignancies.
The reasons for not proceeding to biopsy for the 37 men
who had a serum PSA test as part of their investigation for
PCa and were referred for urological assessment are not
known for all patients. As a result of ad hoc conversations, it
became evident that a number did not proceed because they
reassessed their level of risk and concluded that the
likelihood of a positive cancer biopsy was reduced and
the risks associated with biopsy were not warranted. We
were unable to confirm whether some of these donors had
biopsies elsewhere.
The need for better diagnostic tests for PCa is undisputed.
We consider that sampling cells and fluid from prostatic
acini is the best noninvasive method for collecting speci-
mens to study, but these have not been easy to obtain for a
number of reasons that include increased costs for donors
and community mores. ED is increasingly a problem as men
age [22]. The median age of contributors was 63.5 yr, with
38.9% (113/290) older than 65 yr, which is surprising given
the expected reticence for this age group towards to a
request to provide an ejaculate specimen during 1993–
2003. Patients younger than 50 yr constituted only 8.6% of
the donor population.
All participants were members of a highly selected
group. Ordinarily, this would lessen the value of the study.
However, with the ongoing need to identify at-risk men
who will live long enough to benefit from diagnosis and
treatment of PCa should it be detected, these findings are
particularly relevant and reassuring. According to the
premise that the ejaculate donor cohort represented men
with favourable survival prospects beyond erectile compe-
tence, which by inference includes good cardiovascular
status [12,13], we suspect that their survival outcomes
would be superior compared to a cohort selected purely on
the basis of IIEF or Sexual Health Inventory for Men scores.
However, this contention can only be settled conclusively in
a prospective trial.
It is unknown whether participants in this study used
erection aids. Phosphodiesterase inhibitors only became
available in Australia in 1998 for the first time, with the costs
of purchase expected to have been beyond the reach of most
of the donors. The large majority of the participants were
public patients (93%), a population group recognised to have
poorer outcomes for both overall and cancer survival as a
consequence of lower socioeconomic status [23–25].
Accurate determination of cause of death and separation
of those who died into categories on the basis of death
certificates are always problematic. There are differences
between individual assessors attributing cause of death [26]
and often marked differences between death certificates
and autopsy findings [27]. By comparing survival between
individuals not diagnosed with PCa and individuals who
were, we avoid this problem.
Although ability to produce an ejaculate specimen
does not always reflect normal erectile capability, it isimprobable that those who volunteered and donated
specimens on demand had significant ED. Furthermore,
willingness to provide and then donate an ejaculate
specimen for research is much more than an indicator of
whether or not ED and, by inference, underlying cardio-
vascular morbidity are present, so such donation may bring
new meaning to the term performance index, possibly
extending the independent prognostic significance of high
Eastern Cooperative Oncology Group scores and Karnovsky
index ratings in clinical trials.
5. Conclusions
In conclusion, the study results strongly support the
hypothesis that volunteers who provided ejaculate speci-
mens for our research studies have a high survival rate.
Furthermore, they indicate that life expectancy tables may
serve as a ready reference to indicate probable survival for
ejaculate donors diagnosed with PCa, especially for those
aged >65 yr.
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